Navigation Links
Better Prostate Cancer Survival for Men Taking Statins
Date:10/31/2007

Study finds 10% improvement with cholesterol drugs

WEDNESDAY, Oct. 31 (HealthDay News) -- Men who were taking statins to lower their cholesterol had a 10 percent greater chance of being cured of prostate cancer by radiation therapy 10 years after diagnosis, a new study finds.

It's an "intriguing and very interesting finding," but falls short of supporting statin use for all prostate cancer patients, said study author Dr. Michael J. Zelefsky, a professor of radiation oncology at Memorial Sloan-Kettering Cancer Center in New York City. He was to deliver the results Wednesday at the American Society for Therapeutic Radiology and Oncology annual meeting, in Los Angeles.

"But I would encourage men to see their internist and get on the medications if their blood cholesterol warranted it," he said.

Zelefsky reported on 871 men given radiation therapy for prostate cancer between 1995 and 2000. The five-year relapse-free survival rate for the 168 men taking statins was 91 percent while the 10-year survival rate was 76 percent. That compares to 81 percent and 66 percent, respectively, for those not taking the drugs.

"There have been some reports of a lower risk of developing prostate cancer for those men who have been on statins," Zelefsky said, but the possible mechanisms by which the drugs might help prevent the disease or cure it are unknown.

"There was a suggestion made of a possible added benefit by an interaction between the drug and radiation," he said. "Or does it have its own independent effect? That is possible as well."

Zelefsky added that this study, and others suggesting a beneficial effect of statins on prostate cancer, "give fuel to stimulate what is the only way to absolutely corroborate such an effect, in a randomized, controlled trial."

Dr. Eric Horwitz, clinical director of radiation oncology at the Fox Chase Cancer Center in Philadelphia, said he agreed with Zelefsky's call for a tightly monitored clinical trial. "There has been great success in running these large tests, and I'm sure it can be done."

As it is, many men diagnosed with prostate cancer are already taking statins, and there is no reason for them to stop, Horwitz said. "This report is reassuring because of the overlap," he noted.

Two recent reports have linked statin use with a lower risk of developing prostate cancer. One study, from the University of Alabama, Birmingham, found a decline in prostate cancer death rates that was most notable among white men who used statins.

Another study, from Duke University Medical Center, found lower blood levels of prostate-specific antigen, a potential marker of the cancer, among men taking statins.

A study on statin use in prostate cancer prevention or treatment should center on men at higher risk, Zelefsky said -- "Older men with a family history."

There is "no significant downside" to statin use in such studies because the drugs have a low rate of adverse side effects, he said.

More information

For more on prostate cancer, visit the U.S. National Cancer Institute.



SOURCES: Michael J. Zelefsky, M.D., professor, radiation oncology, Memorial Sloan-Kettering Cancer Center, New York City; Eric Horwitz, M.D., clinical director, radiation oncology, Fox Chase Cancer Center, Philadelphia; Oct. 31, 2007, presentation, American Society for Therapeutic Radiology and Oncology annual meeting, Los Angeles


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Homeopathic preparation better than placebo in perennial allergic
2. Patient’s perception of health status helps in better recover
3. For better mood and energy!! Work-up in short span
4. Antifever drug betters stroke outcome
5. Prevention is better than cure
6. Better prostate cancer detection
7. A better way to measure cholesterol
8. Sponging Cattle betters spraying in eradicating Malaria
9. New Computerized Imaging Systems Help In Better Dental Treatment Planning
10. New therapy better at increasing bone density
11. Better Treatment for obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades ... for each job, ensuring the best suited solution to meet regulatory requirements. Their ... at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, president ... the development of technological innovations that lead to broad-based healthcare solutions. , “Jon ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual ... 1 billion women around the world who do not have access to a toilet, even ... US about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... patient Services To Begin In June , Aloria Health, specializing in a re-imagined, ... opening of Aloria Milwaukee, its first treatment facility for outpatient, day treatment and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... tick-borne disease research and education, today announced that it has named Scott Santarella ... the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where he ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 20, 2016 According to the 2016 ... increasing demand for affordable healthcare solutions as since the early ... rise. In countries like the US, the healthcare cost rose ... the consumer price index inflation rate stood at an average ... up to 3.62% during the same time period. This can ...
(Date:5/19/2016)... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced today that it is ... a chance to meet iconic entertainer Mario Kreutzberger ... past two years has been the face of the company,s ... with type 2 diabetes, which Don Francisco is ... and tips for long-term healthy lifestyle choices. ...
(Date:5/19/2016)... , The data will be presented ... 8006)   The conclusions of the study point to ... with 90% of the m presenting duration ... two percent of the patients had clinical benefit.   ... Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients ...
Breaking Medicine Technology: